You have no items in your shopping cart.
Product Details
| Cat # +Size | 1567-25 |
|---|---|
| Size | 25 mg |
| Alternate Name | (1S,2S,3R,4S,7R,9S,10S,12R,15S)-4,12-Diacetoxy-15-{[(2R,3S)-3- (benzoylamino)-2-hydroxy-3- phenylpropanoyl]oxy}-1,9- dihydroxy-10,14,17,17-tetramethyl -11-oxo-6-oxatetracyclo [11.3.1.0~3,10~.0~4,7~] heptadec-13-en-2-yl rel-benzoate |
| Appearance | White solid |
| CAS # | 33069-62-4 |
| Molecular Formula | C₄₇H₅₁NO₁₄ |
| Molecular Weight | 853.92 |
| Purity | ≥99% |
| Solubility | DMSO (50 mg/ml) |
| SMILES | CC1=C2C(C(=O)C3(C(CC4C(C3C(C(C2(C)C)(CC1OC(=O)C(C(C5=CC=CC=C5)NC(=O)C6=CC=CC=C6)O)O)OC(=O)C7=CC=CC=C7)(CO4)OC(=O)C)O)C)OC(=O)C |
| InChi | InChI=1S/C47H51NO14/c1-25-31(60-43(56)36(52)35(28-16-10-7-11-17-28)48-41(54)29-18-12-8-13-19-29)23-47(57)40(61-42(55)30-20-14-9-15-21-30)38-45(6,32(51)22-33-46(38,24-58-33)62-27(3)50)39(53)37(59-26(2)49)34(25)44(47,4)5/h7-21,31-33,35-38,40,51-52,57H,22-24H2,1-6H3,(H,48,54)/t31-,32-,33+,35-,36+,37+,38-,40-,45+,46-,47+/m0/s1 |
| InChi Key | RCINICONZNJXQF-MZXODVADSA-N |
| PubChem CID | 36314 |
| MDL Number | MFCD00869953 |
| Handling | Protect from moisture |
| Storage Conditions | -20°C |
| Shipping Conditions | RT |
| USAGE | For Research Use Only! Not For Use in Humans. |
Details
An Antitumor and antileukemic agent. Promotes assembly of microtubules and inhibits tubulin disassembly
Why buy BioVision Products?
 |
 |
 |
 |
Innovation |
Affordability |
Global Presence |
Technical Support |
BioVision aims to provide our customers innovative tools for accelerating drug discovery and biological research. BioVision offers >8,000 products including the most comprehensive array of assay kits for key targets in Metabolic pathways. |
BioVision is committed to providing the highest quality products at a competitive price. |
We have a broad network of global distributors who are ready to address your research needs and ensure fast delivery. |
Our highly trained Technical Support team provides comprehensive product support and is dedicated to resolving your issues quickly and efficiently. |
Wang, Wei-Jan et al. (2017) Inhibition of the EGFR/STAT3/CEBPD Axis Reverses Cisplatin Cross-resistance with Paclitaxel in the Urothelial Carcinoma of the Urinary Bladder, Clin Cancer Res. 2017 Jan 15;23(2):503-513.
For more citations of this product click here
